402

THE EFFECT OF NLRX1 ACTIVATION ON EOSINOPHILS IN ULCERATIVE COLITIS AND INFLAMMATION: TRANSLATIONAL LEARNINGS ACROSS DISEASES AND FROM MOUSE TO HUMAN

Date
May 19, 2024

Background: Although the precise role of eosinophils in IBD is debated, elevated eosinophils may influence response to therapy and clinical outcomes1. Thus, therapeutic agents which affect both neutrophil and eosinophil recruitment may provide more robust clinical improvement in patients with UC. NLRX1 is an immunometabolic protein which reduces oxidative stress, shifts cellular metabolism, and decreases inflammation in multiple cell types implicated in ulcerative colitis (UC). Studies of NLRX1 agonists (gut-selective NX-13 & systemic LABP-73) in diverse disease models identified novel cellular targets of NLRX1 activation. We compared NLRX1’s effect on eosinophils in two disease states, UC and the more prototypical eosinophilic disease, asthma, and evaluated the findings.
Methods: In the 4-week NX-13 Phase 1b, a double-blind trial of 36 patients with active UC (Total Mayo Score 4-10; Mayo endoscopic subscore 2-3) who were randomly assigned to NX-13 250mg Immediate Release (IR), 500mg IR, 500mg Delayed Release (DR) or Placebo QD for 4 weeks, histology was assessed using the Geboes score by a blinded pathologist2.For allergic asthma models, mice were immunized with ovalbumin or house dust mite followed by antigen challenge concurrent with LABP-73 or vehicle. Cells isolated from the lung were analyzed by flow cytometry using the BD FACS Celesta / Diva system. Data are represented as means (standard error).
Results: In the 1b clinical trial, both the Geboes score and neutrophil subscores were reduced in the IR NX-13 group compared to placebo, consistent with the effects seen in preclinical IBD models. Upon examination, eosinophil infiltration was reduced in both the IR dose cohorts compared to placebo (Fig1A). In the subset of patients with active eosinophil infiltration at baseline (defined as Geboes subscore ≥2A.1), eosinophil reduction was seen in all NX-13 doses (Fig1B). Importantly, a numerically increased clinical response rate (decrease in total Mayo score of ≥3 or ≥30%) was seen in patients that demonstrated effective eosinophil reduction, compared to patients without improvement (75% versus 29%; Fisher’s Exact Test, p=0.08). In two allergic asthma models, NLRX1 activation by LABP-73 significantly reduced the fraction of eosinophils within the lung relative to vehicle control (n=7-8; p< 0.05), confirming NLRX1 activation can regulate eosinophilic inflammation in Th2-mediated responses.
Conclusion: Neutrophil and eosinophil infiltration were reduced in UC patients treated with the gut selective NLRX1 agonist, NX-13, and was coupled with better clinical outcomes. The effect of NX-13 on eosinophils will be evaluated further in the ongoing phase 2 NEXUS trial in patients with UC.
Reference:
1 A Mookhoek, et al. JCC (16).
2 L Peyrin-Biroulet, et al. JCC (17) Supp.

Presenter

Speaker Image for Séverine Vermeire
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven

Speakers

Speaker Image for Marla Dubinsky
Icahn School of Medicine, Mount Sinai
Speaker Image for Bram Verstockt
University Hospitals Leuven

Tracks

Related Products

Thumbnail for Kiron and Kamala Das Symposium — Precision Medicine in IBD: The Road Ahead
Kiron and Kamala Das Symposium — Precision Medicine in IBD: The Road Ahead
SOCIETY: AGA With the expansion of IBD treatment options, there is increasingly the need for predictive models to determine which treatments work best for which patients with IBD…
Thumbnail for ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND SUBSTUDY
ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND SUBSTUDY
BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
Thumbnail for EFFICACY AND SAFETY OF THE ORAL SELECTIVE SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR MODULATOR VTX002 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 TRIAL
EFFICACY AND SAFETY OF THE ORAL SELECTIVE SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR MODULATOR VTX002 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 TRIAL
BACKGROUND: VTX002 is a novel oral selective sphingosine-1-phosphate-1 (S1P1) receptor modulator in development for the treatment of ulcerative colitis (UC)…